# An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

> **NCT01932125** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 100 (actual)

## Conditions studied

- Ovarian Neoplasms
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01932125
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-05
- **Primary completion:** 2025-06-18
- **Final completion:** 2025-06-18
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01932125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01932125, "An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01932125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*